Clinical Study
Characteristics and Results of the Management of Diffuse Large B-Cell Lymphomas: The Experience of Côte d'Ivoire
Table 4
Therapeutic and evolutional characteristics of patients.
| | Parameters | Number (%) |
| | Type of therapy | | | CHOP | 63 (100) | | RCHOP | 0 (0) | | Therapeutic response | | | Complete remission | 27 (43) | | Partial remission | 25 (40) | | Failure | 11 (17) | | Dose adherence | | | Normal | 61 (97) | | Reduction | 2 (3) | | Delay of chemotherapy (days) | | | <15 | 44 (70) | | 15–30 | 14 (22) | | >30 | 5 (8) | | Treatment compliance | | | Good | 27 (43) | | Poor | 36 (57) | | Toxicity | | | Hematological | 23 (37) | | Metabolic | 20 (32) | | Digestive | 7 (11) | | Cardiac | 3 (5) | | Neuropathies | 3 (5) | | Alopecia | 2 (3) | | Number of cycles | | | 4–7 | 46 (73) | | >7 | 17 (27) | | Outcome at median follow-up | | | Progression-free survival | 20 (32) | | Overall survival | 31 (49) | | Lost to follow-up | 8 (13) | | Dead | 32 (51) | | Causes of death | | | Progression | 17 (27) | | Hematological toxicity | 7 (11) | | Infection | 4 (6) | | Metabolic toxicity | 2 (3) | | Undetermined | 2 (3) |
|
|
